



# Guideline for the pharmacological treatment of hypertension in adults

**WEB ANNEX B**

**Evidence-to-decision frameworks**



**World Health  
Organization**

Guideline for the pharmacological treatment of hypertension in adults. Web Annex B. Evidence-to-decision frameworks

ISBN 978-92-4-003400-6 (electronic version)

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Guideline for the pharmacological treatment of hypertension in adults. Web Annex A. Summary of evidence. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication forms part of the WHO guideline entitled *Guideline for the pharmacological treatment of hypertension in adults*. It is being made publicly available for transparency purposes and information, in accordance with the *WHO handbook for guideline development*, 2nd edition (2014).

## Contents

Acronyms and abbreviations.....	3
PICO question 1: At what level of blood pressure should pharmacological therapy be started to prevent cardiovascular events? .....	4
PICO question 2: Is any laboratory testing necessary prior to initiation or during titration of pharmacological treatments? .....	10
PICO question 3: Should cardiovascular risk assessment be used to guide initiation of antihypertensive medications?.....	14
PICO questions 4–5: In adults with hypertension requiring pharmacological treatment, which drugs should be used as first-line agents? In adults with hypertension requiring pharmacological treatment, which drugs (BB, CCB, diuretics, ACE, or ARB vs BB, CCB, diuretics, ACE, or ARB in head-to-head studies) should be used as first-line agents?.....	18
PICO question 6: In adults with hypertension requiring pharmacological treatment, which drugs (monotherapy using BB, CCB, diuretics, ACE or ARB vs combination therapy using BB, CCB, diuretics, ACE or ARB) should be used as first-line agents? .....	24
PICO question 7: In adults with hypertension requiring pharmacological treatment, which drugs combination therapy of two or more drugs (BB, CCB, diuretics, ACE, or ARB) vs different combination therapy of two or more drugs (BB, CCB, diuretics, ACE, or ARB) should be used as first-line agents?.....	29
PICO question 8: In adults with hypertension requiring pharmacological intervention, is use of a single-pill combination of antihypertensives drugs associated with improved outcomes? .....	33
PICO question 9: What target BP should pharmacologic treatment aim to achieve? .....	38
PICO question 10: In adults with hypertension given pharmacological treatment, when should BP be reassessed?.....	45
PICO question 11: Can pharmacological management of hypertension be provided by nonphysician care providers? .....	49
References.....	55

## Acronyms and abbreviations

ACE1	angiotensin-converting enzyme 1
ACE2	angiotensin-converting enzyme 2
ACEi	angiotensin-converting enzyme inhibitor
AE	adverse events
ARB	angiotensin-II-receptor blocker
BB	beta-blocker
BP	blood pressure
CAD	coronary artery disease
CCB	calcium channel blocker
CKD	chronic kidney disease
CV	cardiovascular
CVD	cardiovascular disease
DBP	diastolic blood pressure
DM	diabetes mellitus
ECG	electrocardiogram
GDG	Guideline Development Group
eGFR	estimated glomerular filtration rate
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HCW	health care worker (nonphysician)
HF	heart failure
HIC	high-income country
HTN	hypertension
ICER	incremental cost-effectiveness ratio
LIC	low-income country
LVH	left ventricular hypertrophy
MACE	major adverse cardiovascular event
MI	myocardial infarction
MIC	middle-income country
NCD	noncommunicable disease
PICO	population intervention comparator outcome
QALY	quality-adjusted life year
RAAS	renin-angiotensin-aldosterone system
RCT	randomized-controlled trial
RR	relative risk
SBP	systolic blood pressure
SES	socioeconomic status

PICO question 1: At what level of blood pressure should pharmacological therapy be started to prevent cardiovascular events?

	CRITERIA	JUDGEMENTS	RESEARCH EVIDENCE/PANEL INPUT
VALUES	Is there important uncertainty or variability about how much people value the main outcomes?	<p>Important uncertainty or variability    Possibly important uncertainty or variability    Probably no important uncertainty or variability    No important uncertainty or variability    No known undesirable outcomes</p> <p><input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/></p> <p>Detailed judgements</p>	<p><b>RESEARCH EVIDENCE</b></p> <p><b>Societal/clinical/public health:</b> HTN treatment is generally highly valued from a public health and clinical perspectives (largest disease burden among NCD risks worldwide; population and long-term clinical outcome perspectives).<sup>1 2</sup></p> <p><b>Patient perspective:</b> When given for primary prevention, antihypertensive therapy represents a lifelong daily medication regimen for an asymptomatic condition; treatment may be perceived as low value from the asymptomatic patient perspective unless the person is convinced of a trade-off between immediate inconvenience/side-effects and potential long-term health gains.<sup>3 4</sup></p> <p><b>PANEL INPUT</b></p> <p><b>Age dependence:</b> young and asymptomatic people may not appreciate the benefit. There are differences in values based on race, gender, baseline BP, socioeconomic status, education, dependence. Those with home monitoring capacity may have a different view.</p>
BENEFITS AND HARMS OF THE OPTIONS	What is the overall certainty of the evidence of effects?	<p>No included studies    Very low    Low    Moderate    High</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/></p> <p>Detailed judgements</p>	<p><b>RESEARCH EVIDENCE</b></p> <p>On average, benefits are 5–10/1000 CV events/death and harms (side-effects) are 20–30/1000. Harms are mostly not serious and have variable severity, could be a surrogate outcome such as rise in creatinine that may not be clinically relevant. On the other hand, benefits were major events (reduction in mortality, cardiovascular mortality, stroke, MI and heart failure events.).</p>
	How substantial are the desirable anticipated effects?	<p>Don't know    Trivial    Small    Moderate    Large    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/></p> <p>Detailed judgements</p>	<p>The benefits clearly outweigh harms. SBP threshold of 140 or above has the clearest benefit/risk balance, as opposed to a lower threshold of 130 in those with comorbidities.</p> <p>The certainty is high to moderate overall, varies according to the BP level.</p>
	How substantial are the undesirable anticipated effects?	<p>Don't know    Trivial    Small    Moderate    Large    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/></p> <p>Detailed judgements</p>	<p><b>PANEL INPUT</b></p> <p>When CKD patients are recruited they already have been treated; thus it is difficult to assess their baseline BP, may not be unethical to study in RCT. Progression is slow and requires longer follow up for kidney disease outcomes. CV benefit is likely underestimated. Evidence from patients with CAD or DM can be extrapolated to CKD.</p>

	<p><b>Do the desirable effects outweigh the undesirable effects?</b></p>	<p>No    Probably No    Don't know    Probably Yes    Yes    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/></p> <p><b>Detailed judgements</b></p>	<p>The risk of adverse events is twice that of placebo in treated CVD patients<sup>5</sup>. However, clinical significance of composite adverse events risk is not well established as the composite includes both mild and severe AEs. Evidence on harms is also mixed because of different amounts of BP lowering in trials and use of different classes and molecules of anti-HTN agents.</p> <p>The treatment trials have enrolled individuals with higher CV risk, thus, the results may be indirect when applied to lower risk, wider population.</p>
<p><b>RESOURCE USE</b></p>	<p><b>How large are the resource requirements?</b></p>	<p>Large costs    Moderate costs    Small    Moderate savings    Large savings    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/></p> <p><b>Detailed judgements</b></p>	<p><b>RESEARCH EVIDENCE</b></p> <p>Cost data is available from various countries such as the United States<sup>6 7 8</sup>, China<sup>9</sup>, and India<sup>10</sup>.</p> <p><b>PANEL INPUT</b></p> <p>Resources vary based on the public health system structure and the country economic status.</p> <p>Refugees have limited resources and depend on donated medications and samples. Even in the US, un- or under-insured people may choose food over BP meds. May choose to treat other conditions over HTN.</p> <p>Cost in low-income countries is sometimes higher than other countries.</p> <p>Prevention of CV events may lead to health savings.</p> <p>Cost of screening is to be considered when discussing thresholds of starting treatment. Resource allocation is large for population-based systematic HTN screening of the whole adult population to detect 140–159 SBP; but note that population screening is needed to identify higher BP groups (SBP ≥160 mmHg) anyway. Opportunistic screening in health facilities is more resource efficient and the logical first step for jurisdictions starting with low awareness of HTN and low HTN control rates. Identifying most existing CVD patients with SBP 130–139 should be relatively easy since they are usually known to the health system, but treatment of this relatively small group alone would mean much smaller population health impact.</p> <p><b>Medications:</b> few lower income countries currently most likely do not allocate sufficient funds toward treating all of their hypertensive patients, but this information is not readily available.</p> <p><b>Human resources:</b> Team based care involving task-sharing can make HTN treatment more affordable from a human resources perspective.</p>

	<p><b>How large is the incremental cost relative to the net benefit?</b></p>	<p>Very large ICER    Large ICER    Moderate ICER    Small ICER    Savings    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/></p> <p><b>Detailed judgements</b></p>	<p><b>RESEARCH EVIDENCE</b></p> <p>Multiple sources of cost effectiveness are available from various countries such as the US, UK, Nigeria and Argentina<sup>11 12 13 14 15 16</sup> and for lower thresholds and higher risk individuals.<sup>17 18 19</sup> Most cost-effectiveness estimates were clustered below USD 1000 per averted DALY – well below the average 2017 GDP per capita for lower-middle income countries of USD 2188,<sup>20</sup> suggesting they could be very cost-effective for lower-middle income countries. Per Kostova study<sup>11</sup>, WHO, and Disease Control Priorities 3 study, HTN treatment (treating all with BP <math>\geq 140/90</math> mmHg) is cost-effective and a “best buy” intervention. Treating high risk/CVD patients with baseline 130–139 mmHg shown to be cost-effective, but not cost saving (SPRINT<sup>18</sup>); value depends on maintaining the intervention effect &gt;5 years.</p> <p><b>PANEL INPUT</b></p> <p>Cost relative to benefit is likely small to moderate. Generic drugs will clearly lower the cost.</p>
<p><b>EQUITY</b></p>	<p><b>What would be the impact on health inequities?</b></p>	<p>Increased    Probably increased    Uncertain    Probably reduced    Reduced    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/></p> <p><b>Detailed judgements</b></p>	<p><b>RESEARCH EVIDENCE</b></p> <p>Barriers in access to HTN care in low-income settings include low patient health literacy, lack of financial protections, and limited resources.<sup>21</sup> Out-of-pocket payments for chronic, lifelong medicines and consultations can be impoverishing.</p> <p><b>PANEL INPUT</b></p> <p>Treating group with SBP 130–139 mmHg has potential to draw resources away from finding unaware population with HTN or from controlling BP in people with baseline <math>\geq 140/90</math> mmHg.</p>
<p><b>ACCEPTABILITY</b></p>	<p><b>Is the option acceptable to key stakeholders?</b></p>	<p>No    Probably No    Uncertain    Probably Yes    Yes    Varies</p> <p><input type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/>    <input checked="" type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/></p> <p><b>Detailed judgements</b></p>	<p><b>RESEARCH EVIDENCE</b></p> <p><b>Patients:</b> patients don't perceive risk of HTN and may find it hard to accept daily medication regimen, especially when minor side-effects persist (e.g. mild but bothersome pedal oedema with Ca<sup>++</sup> blocker).<sup>22</sup></p> <p><b>Clinicians:</b> trials evidence very solid and holds up to very conservative analyses.</p> <p><b>Governments:</b> familiar, simple, easy to implement, though there is a cost, especially medications, screening.</p>

FEASIBILITY	Is the option feasible to implement?	No	Probably No	Uncertain	Probably Yes	Yes	Varies	<p><b>RESEARCH EVIDENCE</b></p> <p>The many barriers in access to HTN care in low-income settings include overburdened health-care providers; the lack of an organizational structure to accommodate nonphysicians as part of a primary care team; the lack of confidence and/ or policy towards the nonphysician providers' ability to manage uncomplicated and stable patients; and the lack of infrastructure for data collection and longitudinal monitoring of clinical information on an ongoing basis.<sup>21 23</sup></p> <p><b>PANEL INPUT</b></p> <p>It varies based on health system structure and commitment of the country/health system. However, likely feasible in most countries.</p>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23649](https://www.yunbaogao.cn/report/index/report?reportId=5_23649)

